Biomarker-Based Immunoassays Market Size, Share, Trends, & Industry Analysis Report By Sample Type, By Product, By Biomarker Type, By Disease Indication, By End User, and By Region – Market Forecast, 2025–2034

The biomarker-based immunoassays market size is expected to reach USD 8.86 Billion by 2034, according to a new study by Polaris Market Research. The report “Biomarker-Based Immunoassays Market Share, Size, Trends, Industry Analysis Report: By Sample Type, By Product, By Biomarker Type, By Disease Indication, By End User, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Biomarker-based immunoassays provide reliable tools for early disease detection, monitoring, and personalized treatment across chronic and age-related conditions. These solutions include reagents, kits, instruments, and services, supporting hospitals, diagnostic laboratories, and research institutes with accurate, efficient, and scalable testing options.

Market growth is driven by rising prevalence of chronic diseases, increasing routine biomarker testing, and growing healthcare expenditure. Moreover, adoption of multiplex assays, AI-assisted analysis, and point-of-care testing enhances diagnostic accuracy, patient outcomes, and clinical efficiency globally.

Biomarker-Based Immunoassays Market Report Highlights

Based on sample type, blood samples dominated in 2024, driven by widespread clinical adoption and standardized protocols.

In terms of product, the reagents & kits dominated in 2024 driven by high demand for assay components.

Based on biomarker type, the predictive & prognostic biomarkers dominated in 2024 due to their role in treatment selection.

In terms of disease indication, the cancer dominated in 2024 due to high prevalence and demand for early detection.

Based on end user, hospitals dominated in 2024, fueled by high patient volumes and advanced diagnostic infrastructure.

North America dominated in 2024, backed by strong healthcare systems and government support for chronic disease management.

Asia Pacific projected fastest CAGR, fueled by expanding diagnostic networks, rising chronic disease prevalence, and improving healthcare accessibility.

Key players in the global market include Abbott Laboratories, Thermo Fisher Scientific Inc., Siemens Healthineers, Roche Diagnostics, Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Merck KGaA, Agilent Technologies, Inc., Fujirebio, Quanterix, EKF Diagnostics, and Quibim.

Polaris Market Research has segmented the market report based on sample type, product, biomarker type, disease indication, end user, and region:

By Sample Type Outlook (Revenue, USD Billion, 2020–2034)

Blood

Tissue

Urine

Saliva

Others

By Product Outlook (Revenue, USD Billion, 2020–2034)

Reagent & Kits

Consumables

Instruments/Analyzers

Services

By Biomarker Type Outlook (Revenue, USD Billion, 2020–2034)

Efficacy & Pharmacodynamic Biomarkers

Safety & toxicity biomarkers

Predictive & Prognostic Biomarkers

Surrogate/Exploratory Biomarkers

By Disease Indication Outlook (Revenue, USD Billion, 2020–2034)

Cancer

Cardiovascular Diseases

Neurological Diseases

Immunological Diseases

Other Diseases

By End User Outlook (Revenue, USD Billion, 2020–2034)

Hospitals & Clinics

Diagnostic Laboratories

Research & Academic Institutes

Other End Users

By Regional Outlook (Revenue, USD Billion, 2020–2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America Show more